# Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

> **NCT02879643** · PHASE1 · COMPLETED · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 29 (actual)

## Conditions studied

- ALL, Childhood
- Lymphoblastic Leukemia, Acute, Childhood
- Lymphoblastic Leukemia, Acute

## Interventions

- **DRUG:** Marqibo

## Key facts

- **NCT ID:** NCT02879643
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2022-07-29
- **Final completion:** 2024-12-31
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02879643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02879643, "Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02879643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*